Today’s cancer treatments are varied, complicated and costly. By 2021, global cancer drug expenditures are expected to exceed $147 billion, driven primarily by availability and favorable reimbursement of new medicines.

Oncology Analytics provides the critical missing link for health plans by helping to manage the total cost of cancer care. By providing access to current, evidence-based, disease-specific analytics on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, health plans are able to to provide their members with the ability to achieve the best possible outcomes.

Improved outcomes are possible when treatment options are tailored to the unique needs of the patient. Ensuring that patients receive the optimal treatment that balances efficacy, toxicity and affordability lie at the heart of Oncology Analytics’ mission.


Utilization Management, Purpose Built for Oncology

e-Prior Authorization

The Oncology Analytics e-Prior Authorization platform is purpose-built for oncology to efficiently evaluate and approve high-quality and high-value treatments for cancer care.
Read More

Specialty Oncology Case Review

For complex and complicated patient cases, the Oncology Analytics’ Clinical Team facilitates peer-to-peer reviews in which the efficacy of the recommended cancer treatment is always prioritized over the cost of therapy.
Read More

Cancer Care Insights & Analytics

Oncology Analytics offers deep insights and analytics for health plans and providers, helping to drive further development and improvement of cancer care.
Read More


Case Study

Rituxan Treatment for Lymphoma

Oncology Analytics received a request for Rituxan for the treatment of lymphoma in a 62-year-old patient who presented with weakness and fatigue. After reviewing the medical records, it appeared that the available information did not clearly support the requested treatment. An Oncology Analytics medical director consulted with Dr. John Lister, a Pathologist at Johns Hopkins Hospital and a member of Oncology Analytics Distinguished Academic Advisory Board. Dr. Lister, who specializes in hematologic malignancies, concurred that a diagnosis of lymphoma was not established and that treatment was not indicated. Dr. Lister called the treating physician and after a thorough review of the case, it was agreed that treatment was not needed.

Outcome: Rituxan is used to treat a variety of lymphomas. However, this patient did not have evidence of lymphoma. Rituxan has been associated with fatal infusion reactions, kidney failure, bowel obstruction, infections, and other severe side effects. Administering Rituxan would have subjected the patient to the risk of complications without any associated benefit.

Savings: Approximately $6,200 per treatment or approximately $74,000 over 2 years.